相似文献
1
Role of tissue factor in venous thrombosis.
Annu Rev Physiol. 2011;73:515-25. doi: 10.1146/annurev-physiol-042210-121137.
2
Microparticles in hemostasis and thrombosis.
Circ Res. 2011 May 13;108(10):1284-97. doi: 10.1161/CIRCRESAHA.110.233056.
3
Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice.
J Thromb Haemost. 2015 Jul;13(7):1310-9. doi: 10.1111/jth.13002. Epub 2015 Jun 8.
4
Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients.
Blood. 2013 Sep 12;122(11):1873-80. doi: 10.1182/blood-2013-04-460139. Epub 2013 Jun 24.
5
Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size.
J Thromb Haemost. 2017 Nov;15(11):2208-2217. doi: 10.1111/jth.13809. Epub 2017 Sep 20.
6
Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year.
Thromb Res. 2014 Nov;134(5):1093-6. doi: 10.1016/j.thromres.2014.07.041. Epub 2014 Aug 22.
7
Annexin V and tissue factor microparticles as biomarkers for predicting deep vein thrombosis in patients after joint arthroplasty.
Clin Chim Acta. 2022 Nov 1;536:169-179. doi: 10.1016/j.cca.2022.09.011. Epub 2022 Oct 1.
8
Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer.
J Thromb Haemost. 2017 Dec;15(12):2289-2299. doi: 10.1111/jth.13871. Epub 2017 Nov 8.
9
Tumour and microparticle tissue factor expression and cancer thrombosis.
Thromb Res. 2013 Feb;131(2):109-15. doi: 10.1016/j.thromres.2012.11.013. Epub 2012 Dec 11.
10
Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer.
Blood. 2012 Jun 7;119(23):5543-52. doi: 10.1182/blood-2012-01-402156. Epub 2012 Apr 30.
引用本文的文献
1
Mice with reduced protease-activated receptor 4 reactivity show decreased venous thrombosis and platelet procoagulant activity.
J Thromb Haemost. 2025 Apr;23(4):1278-1288. doi: 10.1016/j.jtha.2024.12.031. Epub 2025 Jan 9.
2
Mice with Reduced PAR4 Reactivity show Decreased Venous Thrombosis and Platelet Procoagulant Activity.
bioRxiv. 2024 Oct 17:2024.10.14.617127. doi: 10.1101/2024.10.14.617127.
3
Association of COVID-19 with acute and post-acute risk of multiple different complications and mortality in patients infected with omicron variant stratified by initial disease severity: a cohort study in Hong Kong.
BMC Med. 2024 Oct 14;22(1):461. doi: 10.1186/s12916-024-03630-6.
4
Contribution of FOS in neutrophils to venous thromboembolism via miR-144 based on bioinformatic prediction and validation.
J Cell Mol Med. 2024 Jun;28(11):e18370. doi: 10.1111/jcmm.18370.
5
The influences of selected clotting and fibrinolysis factors on survival of patients with kidney tumors - a prospective study.
Arch Med Sci. 2021 Apr 8;19(4):1003-1010. doi: 10.5114/aoms/128845. eCollection 2023.
6
Cancer-associated venous thromboembolism.
Nat Rev Dis Primers. 2022 Feb 17;8(1):11. doi: 10.1038/s41572-022-00336-y.
7
In silico analyses of blood flow and oxygen transport in human micro-veins and valves.
Clin Hemorheol Microcirc. 2022;81(1):81-96. doi: 10.3233/CH-211345.
8
Liver injury associated with acute pancreatitis: The current status of clinical evaluation and involved mechanisms.
World J Clin Cases. 2021 Dec 6;9(34):10418-10429. doi: 10.12998/wjcc.v9.i34.10418.
9
[Tissue factors and venous thromboembolism in cancer patients].
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Dec 25;49(6):772-778. doi: 10.3785/j.issn.1008-9292.2020.12.13.
10
Post-traumatic pulmonary embolism: incidence, physiopathology, risk factors of early occurrence, and impact outcome. A narrative review.
Am J Cardiovasc Dis. 2020 Oct 15;10(4):432-443. eCollection 2020.
本文引用的文献
1
Current treatment of venous thromboembolism.
Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):372-5. doi: 10.1161/ATVBAHA.109.197145. Epub 2010 Feb 5.
2
Rivaroxaban: a new oral factor Xa inhibitor.
Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):376-81. doi: 10.1161/ATVBAHA.110.202978. Epub 2010 Feb 5.
3
DVT: a new era in anticoagulant therapy.
Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):369-71. doi: 10.1161/ATVBAHA.110.203497. Epub 2010 Feb 5.
4
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.
Clin Cancer Res. 2009 Nov 15;15(22):6830-40. doi: 10.1158/1078-0432.CCR-09-0371. Epub 2009 Oct 27.
5
Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.
Thromb Res. 2010 Jun;125(6):511-2. doi: 10.1016/j.thromres.2009.09.019. Epub 2009 Oct 24.
6
Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty.
Thromb Haemost. 2009 Oct;102(4):728-34. doi: 10.1160/TH09-04-0261.
7
Role of tissue factor in cancer.
J Clin Oncol. 2009 Oct 10;27(29):4834-8. doi: 10.1200/JCO.2009.22.6324. Epub 2009 Sep 8.
8
Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo.
J Exp Med. 2009 Aug 31;206(9):1913-27. doi: 10.1084/jem.20082297. Epub 2009 Aug 10.
9
Factor Xa inhibitors--new anticoagulants for secondary haemostasis.
Hamostaseologie. 2009 Aug;29(3):260-7.
10
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
J Clin Oncol. 2009 Sep 1;27(25):4124-9. doi: 10.1200/JCO.2008.21.7752. Epub 2009 Jul 27.
Zotero 插件